Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3324/haematol.2015.128538 http://scihub22266oqcxt.onion/10.3324/haematol.2015.128538 C4825292!4825292 !26521297     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26521297 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Haematologica 2015 ; 100 (11 ): 1388-95 Nephropedia Template TP {{tp|p=26521297 |t=2015. Complement inhibitors to treat IgM-mediated autoimmune hemolysis |pdf=|usr=}}{{26521297 }} gab.com Text Complement inhibitors to treat IgM-mediated autoimmune hemolysis JO: Haematologica http://www.kidney.de/pget.php?&tw=1&pmid=26521297 #FOAvip Complement activation in autoimmune hemolytic anemia may exacerbate extravascular hemolysis and may occasionally result in intravascular hemolysis. IgM autoantibodies as characteristically found in cold autoantibody autoimmune hemolytic anemia, in cold agglutinin disease but also in a considerable percentage of patients with warm autoantibodies are very likely to activate complement in vivo. Therapy of IgM-mediated autoimmune hemolytic anemia mainly aims to decrease autoantibody production. However, most of these treatments require time to become effective and will not stop immediate ongoing complement-mediated hemolysis nor prevent hemolysis of transfused red blood cells. Therefore pharmacological inhibition of the complement system might be a suitable approach to halt or at least attenuate ongoing hemolysis and improve the recovery of red blood cell transfusion in autoimmune hemolytic anemia. In recent years, several complement inhibitors have become available in the clinic, some of them with proven efficacy in autoimmune hemolytic anemia. In the present review, we give a short introduction on the pathogenesis of autoimmune hemolytic anemia, followed by an overview on the complement system with a special focus on its regulation. Finally, we will discuss complement inhibitors with regard to their potential efficacy to halt or attenuate hemolysis in complement-mediated autoimmune hemolytic anemia. Twit Text FOAVip Complement inhibitors to treat IgM-mediated autoimmune hemolysis ????Haematologica http://www.kidney.de/pget.php?&tw=1&pmid=26521297 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26521297 #FOAvip English Wikipedia <ref>{{Cite pmid|26521297 }}</ref> Complement inhibitors to treat IgM-mediated autoimmune hemolysis #MMPMID26521297 Wouters D ; Zeerleder S Haematologica 2015[Nov]; 100 (11 ): 1388-95 PMID26521297 show ga Complement activation in autoimmune hemolytic anemia may exacerbate extravascular hemolysis and may occasionally result in intravascular hemolysis. IgM autoantibodies as characteristically found in cold autoantibody autoimmune hemolytic anemia, in cold agglutinin disease but also in a considerable percentage of patients with warm autoantibodies are very likely to activate complement in vivo. Therapy of IgM-mediated autoimmune hemolytic anemia mainly aims to decrease autoantibody production. However, most of these treatments require time to become effective and will not stop immediate ongoing complement-mediated hemolysis nor prevent hemolysis of transfused red blood cells. Therefore pharmacological inhibition of the complement system might be a suitable approach to halt or at least attenuate ongoing hemolysis and improve the recovery of red blood cell transfusion in autoimmune hemolytic anemia. In recent years, several complement inhibitors have become available in the clinic, some of them with proven efficacy in autoimmune hemolytic anemia. In the present review, we give a short introduction on the pathogenesis of autoimmune hemolytic anemia, followed by an overview on the complement system with a special focus on its regulation. Finally, we will discuss complement inhibitors with regard to their potential efficacy to halt or attenuate hemolysis in complement-mediated autoimmune hemolytic anemia. |*Autoantibodies/blood/immunology [MESH] |*Complement System Proteins/immunology/metabolism [MESH] |*Immunoglobulin M/blood/immunology [MESH] |Anemia, Hemolytic, Autoimmune/blood/*drug therapy/immunology [MESH] |Animals [MESH] |Complement Activation/*drug effects [MESH] |Complement Inactivating Agents/*therapeutic use [MESH] |Hemolysis/drug effects/immunology [MESH]Complement inhibitors to treat IgM-mediated autoimmune hemolysis (epmc).pdf DeepDyve Pubget Overpricing